Month: May 2024

Release – Bitcoin Depot Partners with New England-Based Convenience Retailer Nouria Energy

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTM

May 23, 2024 8:00 AM EDTDownload as PDF

Company to Install 57 New Bitcoin ATM Kiosks Beginning in Q2 2024

ATLANTA, May 23, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced a new retail partnership with Nouria Energy Corporation (“Nouria”), a leading convenience store brand based in the northeastern U.S. with robust operations across 175 company owned c-stores and fuel retailers. Beginning in Q2 2024, Bitcoin Depot will deploy its kiosks into 57 Nouria locations across Massachusetts, Maine, and New Hampshire.

“We are thrilled to join forces with Nouria, a respected leader in convenience retail, as we continue our ambitious growth journey throughout 2024,” said Brandon Mintz, CEO of Bitcoin Depot. “At Bitcoin Depot, it is our singular mission to provide unparalleled convenience and pioneering solutions to enhance crypto accessibility for our customers. That objective is made possible through synergistic collaboration with our network of like-minded retail partners, and we look forward to our partnership with Nouria in the months ahead.”

“We are excited to partner with Bitcoin Depot to introduce BTM kiosks in Nouria stores, offering our guests exciting new opportunities to engage with cryptocurrency,” said Kristine Modugno, Director of Category Management at Nouria. “We continuously strive to elevate our suite of products and services for guests, and Bitcoin Depot’s products exemplify a customer-centric approach that perfectly aligns with our operational mentality.”

Bitcoin Depot’s products and services provide an intuitive, quick, and convenient process for converting cash into Bitcoin. This allows users to access the broader digital financial system, including using Bitcoin to make payments, transfers, remittances, online purchases, and investments.

The Company has successfully enacted a series of significant growth and expansion initiatives thus far in 2024, serving to reinforce its position as the market share leader in North America. In April 2024, Bitcoin Depot announced a partnership with its first major grocery chain and purchased an additional 2,300 kiosks to meet increased retailer demand. The Company’s momentum was reinforced further by recent expansion into Australia and Puerto Rico along with achieving the largest installed fleet of BTMs in its history by surpassing its goal of signing 8,000 BTM locations ahead of schedule.

About Bitcoin Depot 
Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to Bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with approximately 7,400 kiosk locations as of April 1, 2024. Learn more at www.bitcoindepot.com.   

About Nouria Energy Corporation
Nouria Energy Corporation, founded in 1989, is one of New England’s largest and most trusted family-owned and operated convenience stores and fuel retailers. With a robust C- Store operation of 175 company-owned locations and a vast dealer network, Nouria provides top-tier products, fresh food, and excellent customer service throughout the Northeast. Nouria also owns and operates over 60 independent car wash locations in New England under the Golden Nozzle brand.

Cautionary Note Regarding Forward-Looking Statements
This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “priorities,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Contacts: 

Investors  
Cody Slach, Alex Kovtun  
Gateway Group, Inc.  
949-574-3860  
BTM@gateway-grp.com 

Media  
Christina Lockwood, Brenlyn Motlagh, Ryan Deloney  
Gateway Group, Inc. 
949-574-3860  
BTM@gateway-grp.com 

Source: Bitcoin Depot Inc.

Released May 23, 2024

Nvidia’s $2.5 Trillion Stunner – The Chip That Conquered Wall Street

Posted on by slightbourne@noblecapitalmarkets.com

Nvidia’s explosive earnings sent shockwaves through the markets this week, with the chip giant’s stock skyrocketing over 9% to new all-time highs above $1,000 per share. The stunning results highlighted accelerating demand for Nvidia’s AI chips and platforms, particularly for applications like generative AI. Nvidia now boasts a staggering $2.5 trillion market cap as faith in the company’s AI leadership grows.

The Santa Clara-based company reported blowout Q1 numbers, with revenue rocketing 262% year-over-year to $26 billion. Adjusted earnings per share of $6.12 crushed expectations of $5.65. Nvidia’s Data Center segment, now 86% of total revenue, saw explosive 427% growth as hyperscalers and enterprises doubled down on AI computation. Even gaming revenue grew a robust 37% amid the AI buzz.

Perhaps most impressively, Nvidia projected Q2 revenue guidance of $28 billion, topping analyst estimates by over $1 billion. This guidance implies around 50% sequential growth, highlighting rapidly escalating demand as AI goes mainstream across industries. CEO Jensen Huang cited “strong and accelerating demand” from cloud providers, consumer tech giants, enterprises, automotive, and healthcare customers.

Nvidia’s results and sunny outlook supercharged the stock to new records above $1,040 per share in early trading on Thursday. At these levels, the chip titan’s valuation has more than tripled from just six months ago. While skeptics point to Nvidia’s nosebleed valuation over 50x forward earnings, the market is betting big on sustained hyper growth from AI proliferation.

The AI leader’s stratospheric rise propelled the entire semiconductor sector, with rivals like AMD and Intel notching solid gains. However, Nvidia’s influence now extends far beyond semis, with its breakneck AI momentum driving the entire tech market higher. The Nasdaq 100 jumped nearly 2% on Thursday, hitting new highs.

But Nvidia’s impact has transcended just tech, lifting the broad S&P 500 index to fresh all-time records above 4,600. As the S&P’s largest stock with a whopping 8% weighting, Nvidia’s 10% rally single-handedly lifted the index by nearly 1%. The AI juggernaut has been the prime catalyst carrying markets to new peaks in 2024 as economic concerns have faded.

Beyond the immediate stock surge, Nvidia also announced several shareholder-friendly moves that could sustain positive sentiment. The company unveiled a 10-for-1 stock split effective in June, potentially paving the way for entry into the elite, price-weighted Dow Jones Industrial Average. Nvidia also raised its quarterly dividend by over 20% following a growing trend among tech giants.

While Nvidia’s dizzy ascent has inevitably sparked bubble fears, the company’s execution and AI sector potential look undeniable for now. With a formidable head start over rivals and a rapidly expanding multi-trillion dollar opportunity, Nvidia may just be getting started. The AI revolution is here, and Nvidia is its indisputable leader – strong enough to keep lifting the entire market higher.


Register for Noble Capital Markets Emerging Growth Consumer, Communications, Media & Technology Virtual Equity Conference – June 26th – 27th, 2024

Conduent Inc. (CNDT) – Attractive Appreciation Potential Based on Divestiture Activity

Posted on by cpereira@noblefcm.com


Thursday, May 23, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Divestiture strategy coming to fruition. During 2024, the company made significant progress in an organizational transformation long in the making. After its spinoff from Xerox in 2017, the company had plans to become a more streamlined business. But, it is the current management team that has successfully executed several key divestitures. In our view, the company is on track to become more efficient, with a healthier balance sheet, and with attractive revenue and cash flow growth.

Meeting proceeds target. On May 2, 2024, the company announced that is has agreed to sell its Casualty Claims Solutions business (related to workers’ comp) to MedRisk for $240 million in cash. Notably, we believe the company has now announced the bulk of its divestitures and is in line to achieve its goal of $600-$800 million of net divestiture proceeds. On a gross basis, the company is expecting roughly $900 million in proceeds. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – AdTheorent Named Best AdTech Platform in 2024 Digiday Media Awards

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ADTH

May 22, 2024

NEW YORK, May 22, 2024 /PRNewswire/ — AdTheorent Holding Company, Inc. (Nasdaq: ADTH), a machine learning pioneer using privacy-forward solutions to deliver measurable value for programmatic advertisers, today announced that it has been named “Best AdTech Platform” in the 2024 Digiday Media Awards. The Digiday Media Awards honor the companies that are modernizing digital media.

AdTheorent named “Best AdTech Platform” in the 2024 Digiday Media Awards.

   

AdTheorent is a digital media platform with transformational privacy-forward methods to execute high-performing programmatic digital advertising campaigns for brand and agency customers. Rather than focusing on targeting user IDs, AdTheorent uses advanced data science and machine learning to score ad impressions based on the statistical likelihood that serving ads on such impressions will yield desired campaign business goals. AdTheorent builds custom machine learning models for each campaign goal and deploys them to the platform for automated execution and optimization. In addition, AdTheorent’s groundbreaking algorithm-based and ID-independent audience targeting solution has re-conceptualized what a targetable digital audience can be, leveraging advanced algorithms – not user IDs – to focus campaign delivery within each advertiser’s desired target audience while driving performance. AdTheorent’s privacy-forward approach to digital advertising and its ability to drive superior performance for advertisers sets the company apart from others in the industry. 

“AdTheorent brings a foundationally different approach to programmatic advertising which drives business outcomes for advertisers in a privacy-forward and efficient manner. We remain committed to building and enhancing the most advanced and differentiated machine learning-powered advertising technology and solutions ever deployed in market,” said Jim Lawson, CEO of AdTheorent. “We are honored to win the Digiday Media Award for ‘Best AdTech Platform’ and thank the judges for this valuable recognition.”

The 2024 Digiday Media Awards recognize companies that are modernizing the digital media industry through technology, partnerships, and innovation. Digiday’s panel of industry-leading judges evaluated hundreds of entries to identify the companies or campaigns that clearly demonstrate success based on the following criteria: Innovation, Creativity, Consumer Value, Results and Overall. Digiday’s awards programs are some of the most influential in the industry.

For more information about AdTheorent’s approach, click here.

About AdTheorent
AdTheorent (Nasdaq: ADTH) uses advanced machine learning technology and privacy-forward solutions to deliver impactful advertising campaigns for marketers. AdTheorent’s machine learning-powered media buying platform powers its predictive targeting, predictive audiences, geo-intelligence, audience extension solutions and in-house creative capability, Studio A\T. Leveraging only non-sensitive data and focused on the predictive value of machine learning models, AdTheorent’s product suite and flexible transaction models allow advertisers to identify the most qualified potential consumers coupled with the optimal creative experience to deliver superior results, measured by each advertiser’s real-world business goals. 

AdTheorent is consistently recognized with numerous technology, product, growth and workplace awards. AdTheorent was named “Best Buy-Side Programmatic Platform” in the 2023 Digiday Technology Awards and was honored with an AI Breakthrough Award and “Most Innovative Product” (B.I.G. Innovation Awards) for five consecutive years. Additionally, AdTheorent is the only seven-time recipient of Frost & Sullivan’s “Digital Advertising Leadership Award.” AdTheorent is headquartered in New York, with fourteen locations across the United States and Canada. For more information, visit adtheorent.com.

(PRNewsfoto/AdTheorent, Inc.)

   

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adtheorent-named-best-adtech-platform-in-2024-digiday-media-awards-302152145.html

SOURCE AdTheorent

Melanie Berger, AdTheorent, melanie@adtheorent.com, 850-567-0082

Release – Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

May 22, 2024 8:00am EDT

Oral Presentation of Tonmya™ (TNX-102 SL) for Fibromyalgia; NDA preparation in progress

Posters Highlighting Other TNX-102 SL Programs In Clinical Development; Long COVID and Acute Stress Disorder

CHATHAM, N.J., May 22, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and present two posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla.

The oral presentation will detail findings of studies of Tonmya (TNX-102 SL, sublingual cyclobenzaprine HCl) in fibromyalgia. One poster will describe the Phase 2 proof of concept study of TNX-102 SL in fibromyalgia-type Long COVID. The second poster will describe the upcoming investigator-initiated Phase 2 trial of TNX-102 SL in treating acute stress disorder and preventing posttraumatic stress disorder after motor vehicle collision, which will be conducted by the University of North Carolina, the sponsor of the study.

TNX-102 SL is a centrally acting, non-opioid medication, which is trade named Tonmya™ for the management of fibromyalgia. As previously announced, the second statistically significant Phase 3 study of Tonmya, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo in participants with fibromyalgia (p=0.00005). Statistically significant and clinically meaningful results (p=0.001 or better) were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function.

Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya for the management of fibromyalgia and has scheduled a Type B pre-NDA meeting with FDA for the second quarter of 2024.

Copies of the Company’s presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the ASCP website here.

Oral Presentation Details

Presenter:Seth Lederman, M.D., Chief Executive Officer
Title:Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine (CBP) HCl) on Mood and Anxiety Symptoms in Fibromyalgia: Results of the Phase 3 RESILIENT Trial
Date/Time:May 29, 2024, 3:00 p.m. ET

Poster Presentation Details

Presenter:Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine
Title:Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on Pain, Sleep, Fatigue and Cognition in Fibromyalgia-Type Long COVID: Results of a Double-Blind Randomized Proof-of-Concept Phase 2 Study
Date/Time:May 30, 2024, 12:30 p.m. ET
Presenter:David Hsu, Ph.D., Senior Scientist
Title:Optimizing Acute Stress Reaction (ASR) Interventions with TNX-102 SL (Sublingual Cyclobenzaprine HCl) – The OASIS Trial: Sustaining Civilian Performance Post-Trauma by Reduction of ASR and Prevention of ASD/PTSD
Date/Time:May 30, 2024, 12:30 p.m. ET

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

1Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Katie Dodge
LaVoieHealthScience
kdodge@lavoiehealthscience.com
(978) 360-3151

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released May 22, 2024

Release – The ODP Corporation Releases 2024 Sustainability Report

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on ODP

Report Presents the Company’s Environmental, Social and Governance (ESG) Practices and Goals

BOCA RATON, Fla.–(BUSINESS WIRE)–May 22, 2024– The ODP Corporation (“ODP,” or the “Company”) (NASDAQ:ODP), a leading provider of products and services through an integrated business-to-business (B2B) distribution platform and omnichannel presence, today announced the release of its 2024 Corporate Sustainability Report, providing information on the Company’s sustainability practices and goals.

“I am excited to share our accomplishments and vision in our latest report for our People, Planet, and Prosperity—our triple bottom line approach to sustainability—with a strong focus on our 5C Culture,” said Gerry Smith, chief executive officer for The ODP Corporation. “We’re proud of our progress toward our sustainability commitments and goals and we will continue working toward creating a sustainable future for our company, our communities, and our planet.”

The 2024 Corporate Sustainability Report presents the Company’s notable achievements from 2023 and ongoing commitment to achieving its sustainability goals, supporting customers in meeting their sustainability commitments and making positive contributions to local communities. Accomplishments highlighted in the 2024 report include:

  • Achieved a 36% reduction in greenhouse gas (GHG) emissions from 2019 (MT CO2e Scopes 1 and 2)
  • Calculated our full scope of GHG inventory for the second year, which helped us set science-based targets and have them validated by SBTi
  • Delivered a 6.7% blended absolute plastic reduction in private label packaging and e-commerce shipping operations in 2023 from a 2022 baseline
  • Diverted 92% of waste from landfills across our distribution center network
  • Raised $5.6 million through in-store and online donations, powered by Round It Up America®, to support Title I public schools

To view the complete 2024 Corporate Sustainability Report or for more information about sustainability at The ODP Corporation, please visit theodpcorp.com/corporate-sustainability.

About The ODP Corporation
The ODP Corporation (NASDAQ:ODP) is a leading provider of products, services, and technology solutions through an integrated business-to-business (B2B) distribution platform and omnichannel presence, which includes world-class supply chain and distribution operations, dedicated sales professionals, a B2B digital procurement solution, online presence and a network of Office Depot and OfficeMax retail stores. Through its operating companies Office Depot, LLC; ODP Business Solutions, LLC; Veyer, LLC; and Varis, Inc., The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.

ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Office Depot is a trademark of The Office Club, LLC. OfficeMax is a trademark of OMX, Inc. Veyer is a trademark of Veyer, LLC. Varis is a trademark of Varis, Inc. ©2024 Office Depot, LLC. All rights reserved. Any other product or company names mentioned herein are the trademarks of their respective owners.

Jennifer Robins
Media Relations
Jennifer.Robins@theodpcorp.com

Swati Joshi
Media Relations
Swati.Joshi@theodpcorp.com

Source: The ODP Corporation

EuroDry (EDRY) – First quarter results hurt by drydocking and vessel damage

Posted on by cpereira@noblefcm.com


Wednesday, May 22, 2024

EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd. into a separate listed public company. EuroDry was spun-off from Euroseas Ltd. on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day- to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Voyage days were down due to drydocking and damage. Two vessels were drydocked, removing the ships from 52 days of service. A damaged boiler on one of the vessels took the ship offline 18 days longer than expected. Decreased utilization meant lower-than-expected revenues.

Drydocking also led to higher costs. Costs rose due to increased drydocking. Fortunately, the boiler repairs will be covered by insurance (not lost days however). Financing costs declined with debt repayment and are poised to drop lower as debt repayments decrease.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comtech Telecommunications (CMTL) – Continuing NG911 Services in Massachusetts

Posted on by cpereira@noblefcm.com


Wednesday, May 22, 2024

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Contract Resigned. Yesterday, Comtech announced that the Commonwealth of Massachusetts approved the execution of a contract with Comtech to continue operations and maintenance of its Next Generation 911 system within the state. The contract follows the renewal of the Washington contract earlier in the year.

Some Needed Good News. Given the recent negative news, the renewal of the Massachusetts contract is some welcomed good news. Significantly, the Massachusetts announcement, combined with the earlier Washington announcement, indicates clients are continuing to work with Comtech even given the turmoil. We view this positively.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – Increasing its Repurchase Program

Posted on by cpereira@noblefcm.com


Wednesday, May 22, 2024

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ability to Buy More Shares. On Monday, CoreCivic filed a form 8-K stating that on May 16, 2024, the Board of Directors authorized an increase of $125 million to the Company’s share repurchase program. The approval raised the overall program to $350 million of common stock. We believe the increase continues management’s philosophy of being opportunistic in repurchases while maintaining a leverage goal of 2.25x-2.75x.

Program’s History. The Board originally approved the share repurchase program in May 2022 for $150 million. The program has since been increased twice, once in August 2022 to $225 million, and now in Monday’s filing. Since the beginning of the program, management has repurchased 13.3 million shares at an average price of approximately $11.99 per share for a total purchase price of $159.3 million. Including the additional authorization, there is approximately $190.7 million remaining under the program.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Biogen’s Bold $1.8B Kidney Disease Treatment Acquisition

Posted on by slightbourne@noblecapitalmarkets.com

Biogen Inc. is doubling down on novel therapies for rare diseases, announcing an acquisition of Human Immunology Biosciences that could be valued at up to $1.8 billion. The deal gives Biogen full rights to HI-Bio’s lead drug candidate felzartamab, which is being studied for several chronic kidney conditions with large unmet medical needs.

The transaction reflects Biogen’s strategic shift under CEO Christopher Viehbacher to diversify beyond its core neuroscience franchise. Just months after the $6.5 billion buyout of kidney disease specialist Reata Pharmaceuticals, Biogen is opening its checkbook again to beef up its pipeline of potential rare disease medicines.

HI-Bio’s felzartamab has completed mid-stage trials for two types of kidney disorders – primary membranous nephropathy and transplant glomerulopathy where the immune system attacks a transplanted organ. Importantly, it is also being evaluated for IgA nephropathy, a leading cause of kidney failure with no approved treatments available.

For Biogen, the deal provides another shot on goal as it navigates an uncertain period. While its newly-launched Alzheimer’s drug Leqembi has shown promise, the company was forced to abandon its previous Alzheimer’s treatment Aduhelm after years of controversy. Biogen’s older multiple sclerosis franchises are facing rising competitive threats as well.

The HI-Bio acquisition gives Biogen added pipeline diversification into nephrology and autoimmune diseases. Felzartamab has a unique approach, as it is an anti-FcRn antibody that targets pathogenic IgG antibodies which can damage kidneys and other organs.

If felzartamab can demonstrate positive efficacy and safety in broader Phase 3 testing, it could eventually have multi-billion dollar peak sales potential across its targeted kidney indications according to analyst forecasts. However, there is no guarantee of clinical or regulatory success.

From a financial perspective, Biogen is paying $1.15 billion upfront for private HI-Bio, along with contingent value rights worth up to $650 million if certain development and commercial milestones are achieved. This is relatively modest compared to Biogen’s $6.5 billion acquisition of Reata announced in February.

The HI-Bio deal continues Biogen’s aim to revamp its R&D pipeline through a series of bold acquisitions and partnerships under Viehbacher. The company is betting that assembling a portfolio of high-risk, high-reward clinical candidates for diseases like Alzheimer’s and kidney disorders will ultimately pay off.

For the healthcare sector and public markets, Biogen’s aggressive business development approach is emblematic of the ongoing consolidation wave. With rising costs of drug development and payer pricing pressures, large biopharma companies are increasingly looking to acquisitions of smaller, more focused biotechs to source external innovation.

While Biogen’s M&A strategy carries substantial financial risk, the HI-Bio deal gives it a promising asset that could reshape treatment for serious kidney diseases if it can overcome the high hurdle of clinical success. For healthcare investors, absorbing Biogen’s evolving pipeline story will be crucial in evaluating the company’s future growth prospects.

Want small cap opportunities delivered straight to your inbox?

The Rise of Generative AI: Unlocking New Investment Frontiers

Posted on by slightbourne@noblecapitalmarkets.com

As the S&P 500 continues its remarkable ascent, hitting fresh record highs, investors are actively seeking the next frontier of growth opportunities. And according to experts, the answer may lie in the rapidly evolving realm of generative artificial intelligence (AI).

During the recent CNBC Financial Advisor Summit, industry leaders shed light on the transformative potential of generative AI and its impact on the investment landscape. Savita Subramanian, head of U.S. equity strategy and U.S. quantitative strategy at Bank of America, boldly proclaimed, “Generative AI is a game-changer.”

The implications of this disruptive technology are far-reaching, with Subramanian predicting that within the next decade, S&P 500 companies will become increasingly efficient and labor-light as they harness the power of generative AI tools. Industries ranging from call centers and financial services to legal services and Hollywood are poised to experience profound changes, opening up new avenues for investment.

But the key lies in identifying the companies and management teams that are best equipped to capitalize on this technological revolution. “What you want to do is figure out which management teams are going to harness the strength and the power of a lot of these new tools and do it first and do it well,” Subramanian advises.

The anticipation surrounding the generative AI revolution is further amplified by the upcoming earnings release from Nvidia, a leading player in the AI space. As a prominent provider of chips for AI applications, Nvidia’s performance and guidance will serve as a bellwether for the entire sector.

Investors eagerly await Nvidia’s report, seeking insights into the demand and growth prospects for AI technologies, as well as the company’s strategies and investments in the generative AI domain. A positive earnings surprise or optimistic outlook from Nvidia could catalyze a surge of investor interest in the AI sector, potentially driving valuations higher for companies at the forefront of this technological wave.

While the Magnificent Seven companies – Apple, Microsoft, Alphabet, Amazon, Nvidia, Tesla, and Meta Platforms – are expected to continue dominating growth, experts like Tim Seymour, founder and chief investment officer at Seymour Asset Management, highlight the opportunities in sectors such as healthcare, industrials, energy, and utilities. Subramanian further emphasizes the importance of a “stock picker’s market,” where investors must carefully evaluate individual companies’ strengths and potential growth drivers.

In this rapidly evolving landscape, diversification and thorough research into individual companies’ AI strategies and capabilities will be crucial for investors seeking to capitalize on the generative AI revolution. As the world stands on the cusp of a technological transformation, those who can identify the trailblazers and early adopters of generative AI may unlock a new frontier of investment opportunities.

The convergence of record market highs, the rise of generative AI, and the imminent earnings release from Nvidia has created a perfect storm for investors to reassess their portfolios and position themselves for the next wave of growth. As the saying goes, “The future belongs to those who prepare for it today.”

Small Cap Stocks Could Soar Next – Here’s Why the Russell Rally May Be Imminent

Posted on by slightbourne@noblecapitalmarkets.com

The major U.S. stock indexes have been on a tear in 2024, with the S&P 500 and Nasdaq Composite recently locking in fresh 52-week highs. However, one area of the market that has yet to fully participate in the rally is small-cap stocks, as represented by the Russell 2000 index. While the Russell 2000 is still up around 4% year-to-date, it has significantly lagged the double-digit gains of its large-cap counterparts.

This underperformance from smaller companies may seem perplexing given the robust economic growth and strong corporate earnings that have powered stocks higher. However, there are a couple potential factors holding small caps back for now.

First, investor sentiment remains somewhat cautious after the banking turmoil of 2023. While the systemic crisis was averted, tighter lending standards could disproportionately impact smaller businesses that rely more heavily on bank financing. Recent upticks in loan activity provide some optimism that credit conditions may be thawing.

The other overhang for small caps has been the aggressive interest rate hiking cycle by the Federal Reserve to combat inflation. Higher borrowing costs weigh more heavily on smaller companies compared to their large-cap peers. However, the Fed is now expected to pivot towards rate cuts later in 2024 once inflation is tamed, providing a potential catalyst for small-cap outperformance.

Historically, small caps have tended to lead coming out of economic downturns and in the early stages of new bull markets. Their higher growth orientation allows them to capitalize more quickly on an inflection in the business cycle. A timely Fed pivot to lower rates could be the rocket fuel that allows the Russell 2000 to start playing catch-up in the second half of 2024.

For investors, any near-term consolidation in small caps may present opportunistic entry points in this economically-sensitive segment of the market. While volatility should be expected, the lofty valuations of large-cap tech and momentum plays leave less room for further upside. Well-managed small caps with pricing power and secure funding could offer asymmetric upside as the economic landscape becomes more hospitable in the latter part of the year.

For long-term investors, any potential small-cap rebound could be particularly compelling given the cyclical nature of small versus large-cap performance. Over decades of market history, there has been a tendency for leadership to rotate between the two size segments. After large caps dominated the past decade, buoyed by the tech titans and slow-growth environment, the economic restart could allow small caps to regain leadership.

From a portfolio construction standpoint, maintaining exposure to both small and large caps can provide important diversification benefits. The low correlation between the size segments helps smooth out overall equity volatility. And for investors already overweight large caps after years of outperformance, trimming some of those positions to reallocate towards small caps could prove timely.

While major indexes continue grinding higher, prudent investors should avoid complacency and think about positioning for what could be a new market regime. Small caps have historically possessed a robust return premium over large caps. As the economic backdrops evolves, 2024 may mark the start of small caps returning to form as drivers of broad market returns once again.

Want small cap opportunities delivered straight to your inbox?

Release – Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

CHATHAM, N.J., May 21, 2024 (GLOBE NEWSWIRE) —  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that EVERSANA® Life Science Services, LLC, a leading provider of commercialization services to the global life sciences industry, completed the initial phase of an assessment of the U.S market opportunity for TonmyaTM (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets), a potential new first line therapy for the management of fibromyalgia. Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya. Specifically, EVERSANA is working with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market (GTM) strategy.

“The primary research and analysis conducted by EVERSANA provides valuable insights and informs the vision for the commercialization of Tonmya,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We are excited to refine our business strategy for the anticipated launch of Tonmya in 2025. It has been approximately fifteen years since patients suffering with fibromyalgia have been provided a new therapeutic option. The market research conducted by EVERSANA with physicians indicates a continued high unmet need, with the need ranked > 4.0 on a 5-point scale.”

Dr. Lederman continued, “We were surprised to learn that opioids dominate the fibromyalgia prescription market, despite the well-known risks of dependency. Opioids are prescribed to more patients following fibromyalgia diagnosis than all the FDA-approved fibromyalgia drugs combined. If approved, we believe that Tonmya can provide a non-opioid, centrally-acting solution for fibromyalgia patients. This is corroborated by EVERSANA’s primary market research in which physicians indicated median interest of 4.0 on a 5-point scale and intended use of Tomya in 40% of their fibromyalgia patients, upon approval.1 We look forward to submitting the NDA for Tonmya in the second half of this year and expect an FDA decision on approval in 2025.”

EVERSANA’s analysis of the market size was based on medical claims databases and epidemiological studies on prevalence and diagnosis2. Primary research with physicians was conducted to test the potential adoption of Tonmya based on its activity and tolerability.  

Key findings from claims data analyses2:

  • ~2.7 million adults in the U.S. currently diagnosed and treated for fibromyalgia.
    • ~90 percent of patients diagnosed with fibromyalgia are female.
  • Percentage of fibromyalgia patients who were prescribed certain drugs3:
    • FDA-approved fibromyalgia drug prescriptions:
      1. Duloxetine (generic Cymbalta®): 23%, pregabalin (generic Lyrica®): 13%, and Savella® (milnacipran): 1%
    • Off-label drug prescriptions:
      1. Gabapentin: 26%, hydroxycodone: 20%, cyclobenzaprine: 18%, oxycodone: 19%, tramadol: 13%, meloxicam: 12%, and amitriptyline: 6%
    • Off-label opioids prescriptions:
      1. Hydroxycodone: 20%, oxycodone: 19%, and tramadol: 13%
  • Targeted prescriber strategy for launch.
    • High prescribers are rheumatologists, pain medicine specialists, primary care physicians, neurologists, and psychiatrists.
  • ~50 percent of diagnosed fibromyalgia patients are covered by Medicare.
    • Medicare population stands to benefit from a decrease in out-of-pocket prescription drug liability to $2,000 per year when the changes from the Inflation Reduction Act are enacted in 2025.

Key findings from primary physician research4:

  • High level of dissatisfaction with currently prescribed drugs.
    • Physicians interviewed estimate that 85% of their patients fail first-line therapy due to efficacy and tolerability issues and 79% of their patients are on multiple therapies.
    • Prescribers indicate high unmet need in fibromyalgia, ranked >4.0 on a 5-point scale.
  • High level of interest in Tonmya from physicians interviewed as a potential new treatment option based on favorable activity and tolerability profile observed in Tonmya fibromyalgia clinical studies.
    • Median interest in Tonmya of 4 on a 5-point scale.
    • Physicians indicated intended use of Tonmya in 40% of their fibromyalgia patients.1

Tonmya is a centrally acting, non-opioid medication. As previously announced, Tonix’s second statistically significant Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results (p=0.001 or better) were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function.

Tonix plans to submit an NDA to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya for the management of fibromyalgia and has scheduled a Type B pre-NDA meeting with FDA for the second quarter of 2024.

1 40% was the median preference share among physicians interviewed, assuming no market access barriers.
2 EVERSANA analysis of claims database, May 2024; commissioned by Tonix
3Note: the total number of patients is greater than 100% because of switching between medications and polypharmacy.
4 EVERSANA primary physician research, May 2024; commissioned by Tonix

About Tonmya* (also known as TNX-102 SL)

Tonmya is a centrally acting, non-opioid, non-addictive, bedtime medication. The tablet is a patented sublingual formulation of cyclobenzaprine hydrochloride developed for the management of fibromyalgia. In December 2023, the company announced highly statistically significant and clinically meaningful topline results in RESILIENT, a second positive Phase 3 clinical trial of Tonmya for the management of fibromyalgia. In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue and improving overall fibromyalgia symptoms and function. RELIEF, the first positive Phase 3 trial of Tonmya in fibromyalgia, was completed in December 2020. It met its pre-specified primary endpoint of daily pain reduction compared to placebo (p=0.010) and showed activity in key secondary endpoints.

*Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

About EVERSANA®

EVERSANA® is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two positive Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase) a biologic designed to treat cocaine intoxication with Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully commercialize any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Katie Dodge
LaVoieHealthScience
kdodge@lavoiehealthscience.com
(978) 360-3151

Matt Braun
EVERSANA
Matt.braun@eversana.com

Source: Tonix Pharmaceuticals Holding Corp.

Released May 21, 2024